CrossAssetDataThe Company File
···
MMED

MiniMed Group, Inc.

MiniMed Group, Inc. is classed by the SEC under Surgical & Medical Instruments & Apparatus (industry code 3841). In its latest annual figures on file, for the fiscal year ended 2026-04-24, it reported revenue of $3.1 billion and a loss of $333 million (its filed statements).

Product business Surgical & Medical Instruments & Apparatus filings since 2025 6 of 9 filed, 3 estimated
Ask the desk about MMED → Compare MMED with WST → Price chart on TradingView ↗ Full EDGAR file ↗ Watch MMED →

Sector peers: WSTICUIGMEDIART

6.4/10headline grade
vs its business-model standard
6.9/10past 7.0/10present 5.0/10future

Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 3841, Surgical & Medical Instruments & Apparatus); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.

The grade, in three tenses

Headline 6.4 out of ten, 6 of 9 metrics filed and 3 estimated: past 6.9 out of ten, present 7.0 out of ten, future 5.0 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.

The nine metrics

  • Surviving crises (past): 8.3 out of ten. No warning events in its filings since 2025. 83rd percentile among 121 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Track record (past): 5.9 out of ten. +12.1% a year over 3 filed years; profitable in 0 of 3. 59th percentile among 105 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Shareholder treatment (past): 6.8 out of ten. CrossAssetData estimate 6.8/10, confidence 35 of 100 (one part). 68th percentile among 119 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
  • Financial health (present): 6.8 out of ten. ROE -9%: lost 9¢ per shareholder dollar. Leverage 22%: owes 22¢ per asset dollar. 68th percentile among 120 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Industry position (present): 6.7 out of ten. top 34% of 109 in its family; net margin -10.7%. 66th percentile among 109 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Leadership (present): 8.0 out of ten. CrossAssetData estimate 8.0/10, confidence 35 of 100 (one part). 80th percentile among 108 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
  • Room to expand (future): 4.5 out of ten. bottom 45% of 104 in its family for room to expand. 45th percentile among 104 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Growth drivers (future): 5.6 out of ten. top 44% of 105 in its family for growth drivers. 56th percentile among 105 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Expectations vs reality (future): 5.1 out of ten. CrossAssetData estimate 5.1/10, confidence 20 of 100 (family median). 50th percentile among 88 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.

The filing record

Newest annual report: Form 10-K filed 2026-06-29 for the period ended 2026-04-24 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-09-08 for the period ended 2026-07-31 (on EDGAR). Newest results release: Form 8-K filed 2026-09-01 (on EDGAR). Newest filing: Form EFFECT, 2026-10-05. Filings on record since 2025. Read from EDGAR 2026-10-12.

Where the revenue comes from

Product and service lines in fiscal 2026: Continuous Glucose Monitoring Systems CGM 50%, Consumables 31%, Pumps 18%, Product and Service Other 2%. By geography: Outside the United States 70%, United States 30%. As tagged in its annual report (Form 10-K, filed 2026-06-29).

Who runs it

Dallara, Que (Chief Executive Officer); Eso, Christopher (President); Spooner, Chad (EVP, Chief Financial Officer); Chandrasena, Gillian (SVP, Chief HR Officer); Gyurci, John (VP, Chief Accounting Officer); Denton, Sheila A. (SVP, Gen. Counsel & Corp. Sec.); Dianaty, Ali (EVP Ch. Prod. & Tech Officer); Wills, Courtney Nelson (SVP, Gen. Counsel, Corp. Sec.); Burman, Linnea (director); Cundy, Scott T (director); and 10 more. 20 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-10-05.

This file: Overview · Past · Present · Future · Filings · every company on file

Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.